Mounjaro VA Coverage Pathway: How Veterans Can Access Tirzepatide

What Is Mounjaro and Why Does It Matter for Veterans?

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes in May 2022. The same molecule received a separate approval under the brand name Zepbound for chronic weight management in November 2023. Tirzepatide works by activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing glycemic control and weight loss that exceeded single-agonist therapies in head-to-head trials.

Veterans carry a disproportionate burden of obesity and metabolic disease. A 2021 analysis published in Obesity found that 66.5% of veterans using VA healthcare had BMI ≥ 30, compared with 41.9% in the general U.S. adult population per CDC NHANES data. Type 2 diabetes prevalence among VA-enrolled veterans reaches approximately 25%, roughly double the national rate according to VA health system surveillance data. These numbers make access to effective GIP/GLP-1 therapy a high-priority clinical question for the VA system.

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% from baseline at 40 weeks, compared with 1.86% for semaglutide 1 mg (P<0.001 for superiority). That head-to-head advantage over an already effective GLP-1 agonist is the reason both VA endocrinologists and veterans themselves are pushing for broader access.

VA Formulary Status and Prior Authorization

Tirzepatide is listed on the VA National Formulary as a non-formulary drug that requires prior authorization (PA) through the VA Criteria for Use (CFU) process. This means a VA provider cannot simply write a prescription. The prescriber must submit clinical justification documenting that the veteran meets specific criteria.

For the type 2 diabetes indication, standard VA PA criteria include: HbA1c above target (typically ≥ 7.0% per ADA Standards of Care 2026) despite metformin at maximally tolerated dose, documented trial or contraindication to at least one formulary-preferred GLP-1 agonist (usually semaglutide or dulaglutide), and evidence of medication adherence. The VA Pharmacy Benefits Management (PBM) service reviews requests and typically responds within 5 to 7 business days.

For obesity without diabetes, the path is more limited. The VA MOVE! program, the system's comprehensive weight-management initiative, has historically relied on older medications like orlistat and phentermine-topiramate. GLP-1 receptor agonists for weight management entered VA prescribing patterns after liraglutide 3.0 mg (Saxenda) gained formulary traction, and semaglutide 2.4 mg (Wegovy) expanded that precedent. Tirzepatide for obesity (as Zepbound) is available at select VA facilities on a case-by-case basis. Ask your VA primary care provider or MOVE! coordinator whether your facility has added it to local formulary criteria.

How the VA Prior Authorization Process Works Step by Step

Getting PA approval requires coordination between the veteran, the prescribing provider, and the VA PBM. Here is the sequence. First, the veteran's VA provider documents the clinical need in the electronic health record (CPRS/Cerner). Second, the provider submits a non-formulary drug request through the VA CFU system, attaching lab values (recent HbA1c, fasting glucose, renal function), prior medication history, and body mass index.

Third, the local VA Pharmacy & Therapeutics (P&T) committee reviews the request against national criteria. Approval rates vary by facility and clinical context. A 2023 analysis in Federal Practitioner found that GLP-1 agonist PA approval rates at VA ranged from 62% to 84% depending on documentation completeness. Fourth, if approved, the prescription routes to the VA mail-order pharmacy (CMOP) or the local VA outpatient pharmacy for dispensing. If denied, the provider can appeal with additional documentation or request a peer-to-peer review with a VA clinical pharmacist.

The entire cycle from submission to dispensing typically takes 10 to 21 days. Veterans can check prescription status through My HealtheVet or the VA Health and Benefits mobile app. One practical tip: ensure your provider includes the specific HbA1c value, the names and dates of prior diabetes medications tried, and the reason each was inadequate. Incomplete documentation is the most common reason for initial denial.

VA Copay Structure for Tirzepatide

VA pharmacy copays are determined by the veteran's priority group assignment, not by drug tier in the traditional commercial-insurance sense. Veterans in Priority Groups 1 through 6 (which includes those with service-connected disabilities rated 50% or higher, former POWs, Purple Heart recipients, and veterans below income thresholds) pay $0 for all outpatient prescriptions, including tirzepatide.

Veterans in Priority Groups 7 and 8, who have higher incomes and no compensable service-connected conditions, pay a flat copay of $11 per 30-day supply for non-formulary medications as of the 2026 VA copay schedule. Compare this with the average retail cash price of $1,023 per month at commercial pharmacies. Even the $11 copay tier represents a 98.9% discount relative to cash pay.

Veterans who have both VA eligibility and commercial insurance (for example, through a civilian employer) should be aware that VA pharmacy benefits and commercial benefits operate independently. You cannot apply a commercial copay card to a VA prescription, and VA will not bill your commercial plan for outpatient medications. However, if the VA denies tirzepatide, your commercial plan becomes a viable backup route, and you may then be eligible for the Lilly Savings Card.

Alternatives When VA Coverage Is Denied or Delayed

Not every PA request succeeds on the first attempt. Several fallback options exist for veterans.

VA Appeal and Peer Review. A denied request can be resubmitted with additional clinical evidence. A letter from an endocrinologist documenting failure of two or more formulary-preferred agents carries significant weight. The VA PBM appeals process allows providers to request direct consultation with a VA clinical pharmacy specialist.

Lilly Savings Card. Veterans who have separate commercial insurance (not VA) can use the Mounjaro Savings Card from Eli Lilly. Eligible patients with commercial coverage may pay as little as $25 per fill, with the card covering up to $150 per 30-day prescription for 24 months. This program explicitly excludes government insurance (VA, Tricare, Medicare, Medicaid) as the primary payer. A veteran using employer-sponsored insurance as the primary payer would qualify.

Compounded Tirzepatide. Under FDA guidance on compounding during shortage, 503A and 503B compounding pharmacies have produced tirzepatide at an average cost of approximately $249 per month. Veterans should note that the FDA added tirzepatide back to the drug shortage list intermittently, and compounded versions are only legally available when the branded product is listed in shortage. Verify current shortage status before pursuing this route. Quality and sterility vary between compounders. Choose a 503B outsourcing facility inspected by FDA over a 503A pharmacy when possible.

Patient Assistance Programs. Eli Lilly's Lilly Cares Foundation provides free medication to uninsured or underinsured patients meeting income criteria (typically at or below 400% of the federal poverty level). Veterans without VA pharmacy access and without commercial insurance should apply directly.

Clinical Evidence: Why Tirzepatide Outperforms Older Options

The VA formulary decision-making process weighs comparative effectiveness data heavily. Here is what the evidence shows.

SURPASS trials (type 2 diabetes). Across the SURPASS program, tirzepatide demonstrated dose-dependent HbA1c reductions. In SURPASS-1 (N=478), tirzepatide 5 mg, 10 mg, and 15 mg reduced HbA1c by 1.87%, 1.89%, and 2.07% respectively versus placebo at 40 weeks. In SURPASS-2 (N=1,879), the 15 mg dose achieved 2.58% HbA1c reduction versus 1.86% with semaglutide 1 mg. SURPASS-4 (N=2,002) showed tirzepatide's cardiovascular safety profile was non-inferior to insulin glargine over 52 weeks, with a 4-point MACE hazard ratio of 0.74 (95% CI: 0.51-1.08).

SURMOUNT trials (obesity). In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared with 2.4% for placebo. That 20.1 percentage-point treatment difference exceeded the 12.4 percentage-point difference seen with semaglutide 2.4 mg in the STEP-1 trial (N=1,961), although cross-trial comparisons carry methodological limitations.

Cardiorenal outcomes. The SURPASS-CVOT trial is evaluating tirzepatide's effect on major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Interim data reported at the 2025 ADA Scientific Sessions indicated a favorable trajectory. Separately, SURMOUNT-MMO is assessing whether tirzepatide reduces mortality and morbidity in adults with obesity.

These data help explain why VA clinicians and P&T committees are increasingly receptive to tirzepatide PA requests, particularly when veterans have documented inadequate response to semaglutide or dulaglutide.

Navigating VA MOVE! and Tirzepatide Together

The VA MOVE! Weight Management Program operates at every VA medical center and many community-based outpatient clinics. It provides multidisciplinary support including nutrition counseling, exercise programming, and behavioral health. MOVE! participation can strengthen a tirzepatide PA request by documenting that the veteran has engaged in structured lifestyle modification, a common requirement for anti-obesity medication approval.

Specifically, VA PA criteria for weight-management medications often require documented MOVE! enrollment or equivalent behavioral intervention for at least 3 to 6 months with less than 5% body weight loss. If you are a veteran considering tirzepatide for weight loss, enroll in MOVE! early. The documentation trail it generates (weigh-ins, dietary logs, counseling notes) becomes the clinical substrate for your PA request.

A 2022 retrospective analysis in Obesity Science & Practice found that veterans who combined GLP-1 agonist therapy with MOVE! participation achieved 3.2% greater body weight reduction at 12 months compared with medication alone. The combination is synergistic, not redundant.

Side Effects and VA-Specific Monitoring

Tirzepatide's adverse effect profile mirrors other incretin-based therapies. The most common events in SURPASS and SURMOUNT trials were gastrointestinal: nausea (12-23% across doses), diarrhea (12-17%), and decreased appetite (5-11%) per the FDA prescribing information. These effects are dose-dependent and tend to diminish after the first 4 to 8 weeks as patients complete the recommended titration schedule: 2.5 mg weekly for 4 weeks, then 5 mg, with incremental increases every 4 weeks to a maximum of 15 mg.

VA primary care teams monitor tirzepatide patients with quarterly HbA1c checks (for diabetes), periodic renal function panels, and regular assessment for signs of pancreatitis or gallbladder disease. Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies (similar to all GLP-1 class agents), and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Veterans with gastroparesis, a history of pancreatitis, or severe GI disease should discuss risk-benefit tradeoffs with their VA gastroenterologist before starting tirzepatide. The Endocrine Society clinical practice guideline on pharmacologic management of obesity recommends stopping therapy if a patient does not achieve at least 5% body weight loss after 12 weeks at the maximum tolerated dose.

How VA Coverage Compares with Tricare and Medicare

Veterans often have overlapping insurance. Here is how tirzepatide access differs across federal programs.

Tricare (active duty, retirees): Tricare covers tirzepatide for type 2 diabetes with PA through Express Scripts. The Tricare retail copay for a non-formulary brand is $77 per 30-day fill. Tirzepatide for obesity (Zepbound) is not covered by Tricare as of early 2026.

Medicare Part D: Coverage varies by plan. Most Part D plans require PA for tirzepatide and restrict it to the diabetes indication. The Medicare Part D coverage gap (formerly the "donut hole") was eliminated for brand-name drugs starting in 2025 under the Inflation Reduction Act, which caps annual out-of-pocket Part D spending at $2,000. Veterans enrolled in both Medicare Part D and VA healthcare should compare costs carefully. The VA $0-$11 copay almost always beats Part D cost-sharing for tirzepatide.

Dual-eligible veterans (VA + Medicare or VA + Tricare) cannot combine benefits on a single prescription. Choose one payer per fill. For tirzepatide, the VA route is nearly always the lowest-cost option if PA is obtainable.